Zc(3900)Z_c(3900) as a DDˉ∗D\bar{D}^* molecule from the pole counting rule

A comprehensive study on the nature of the $Z_c(3900)$ resonant structure is carried out in this work. By constructing the pertinent effective Lagrangians and considering the important final-state-interaction effects, we first give a unified description to all the relevant experimental data available, including the $J/\psi\pi$ and $\pi\pi$ invariant mass distributions from the $e^+e^-\to J/\psi\pi\pi$ process, the $h_c\pi$ distribution from $e^+e^-\to h_c\pi\pi$ and also the $D\bar D^{*}$ spectrum in the $e^+e^-\to D\bar D^{*}\pi$ process. After fitting the unknown parameters to the previous data, we search the pole in the complex energy plane and find only one pole in the nearby energy region in different Riemann sheets. Therefore we conclude that $Z_c(3900)$ is of $D\bar D^*$ molecular nature, according to the pole counting rule method~[Nucl.~Phys.~A543, 632 (1992); Phys.~Rev.~D 35,~1633 (1987)]. We emphasize that the conclusion based upon the pole counting method is not trivial, since both the $D\bar D^{*}$ contact interactions and the explicit $Z_c$ exchanges are introduced in our analyses and they lead to the same conclusion.Comment: 21 pages, 9 figures. To match the published version in PRD. Additional discussion on the spectral density function is include

Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis

<p>Abstract</p> <p>Background</p> <p>Currently, there is no evidence on the combination of lamivudine and thymosin alpha-1 on chronic hepatitis B patients. The aim of this study was to compare the effect of lamivudine monotherapy with that of lamivudine and thymosin alpha-1 combination therapy for the treatment of hepatitis B e antigen (HBeAg)-positive hepatitis B patients.</p> <p>Results</p> <p>We searched PUBMED (from 1966 onwards), EMBASE (from 1966), CBMdisk (Chinese Biomedical Database, from 1978), CNKI (National Knowledge Infrastructure, from 1980), the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews. Eight trials (583 patients in total) were identified. The lamivudine and thymosin alpha-1 combination treatment was significantly superior to lamivudine treatment in terms of ALT normalization rate (80.2% vs. 68.8%, P = 0.01), virological response rate (84.7% vs. 74.9%, P = 0.002), and HBeAg seroconversion rate (45.1% vs. 15.2%, P < 0.00001).</p> <p>Conclusion</p> <p>Among HBeAg-positive patients, thymosin alpha-1 and lamivudine combination therapy may be more effective than lamivudine monotherapy, providing superior rates of biochemical response, virological response, and HBeAg seroconversion.</p

Weekly induction intraperitoneal chemotherapy after primary surgical cytoreduction in patients with advanced epithelial ovarian cancer

BACKGROUND: Traditional intraperitoneal (IP) therapy administered simultaneously with intravenous (IV) chemotherapy in the primary setting has been well documented. This retrospective study was conducted to investigate the role of weekly IP therapy as an inducing intervention before front-line IV chemotherapy, particularly in patients with bulky residual disease after surgery. METHODS: A total of 426 patients with advanced ovarian cancer treated between 1990 and 1999, were reviewed. Follow-up data were available in 409 patients. Of whom, 230 patients received postoperative weekly IP therapy with a median cycles of 4, other 179 patients who did not receive any IP therapy were used as the control group. RESULTS: The median age of the patients was 51 years (range, 20–77 years). One hundred eighty-nine patients with stage III disease and 41 patients with stage IV disease were treated with postoperative IP therapy, respectively. Complications and toxicity were observed in 68 patients (29.5%), but there were no grade 4 toxicities and no patients died of complications or toxicities. In patients with residual disease > 1 cm, the median survival of those with IP delivery of chemotherapy and those without was 21.6 months and 18.8 months, respectively (hazard ratio [HR]= 0.69, P = 0.02). Whereas, in patients with residual disease ≤ 1 cm, the median survival was 46.8 months and 37.6 months, respectively (HR= 0.73, P = 0.09). Multivariate analysis suggested that the factors age ≤ 60 years, stage III, IP therapy and paclitaxel as front-line chemotherapy were associated with a better prognosis for patients with advanced ovarian cancer. CONCLUSION: Weekly postoperative IP therapy as an inducing intervention is practical for both physicians and patients with acceptable complications and associated with a lengthened survival of patients with advanced ovarian cancer. Whether this arm can be used in lieu of a traditional one needs further randomized trial to confirm the preliminary results

Poly[μ2-benzene-1,3-dicarboxyl­ato-κ2 O:O′-μ2-1,3-di-4-pyridylpropane-κ2 N:N′-zinc(II)]

The title compound, [Zn(C8H4O4)(C13H14N2)]n, was obtained by the hydro­thermal reaction of Zn(OAc)2·H2O with 1,3-di-4-pyridylpropane (bpp) and isophthalic acid (H2ip). The ZnII ion is coordinated by two bpp and two ip ligands in a distorted tetra­hedral environment. Each ligand coordinates in a bridging mode to connect ZnII ions into a three-dimensional diamondoid-type structure